memo - Magazine of European Medical Oncology

, Volume 4, Issue 4, pp 248–253

A histology-based algorithm in the molecular diagnosis of mutations of the epidermal growth factor receptor (EGFR)–in non-small-cell lung cancer (NSCLC)*

  • H. Popper
  • F. Wrba
  • U. Gruber-Mösenbacher
  • W. Hulla
  • R. Pirker
  • W. Hilbe
  • M. Studnicka
  • A. Mohn-Staudner
  • F. Ploner
  • Pulmonary Pathology Working Group of the Austrian Society of Pathology/International Academy of Pathology
Consensus report

DOI: 10.1007/s12254-011-0319-7

Cite this article as:
Popper, H., Wrba, F., Gruber-Mösenbacher, U. et al. memo (2011) 4: 248. doi:10.1007/s12254-011-0319-7
  • 55 Downloads

Summary

Patients with stage IIIB and IV non-small-cell lung carcinoma (NSCLC) harbouring activating mutations of the epidermal growth factor receptor (EGFR) gene should be treated first-line with gefitinib or erlotinib, EGFR tyrosine kinase inhibitors (TKI). EGF receptor mutations are most common in adenocarcinomas, especially in the non-mucinous type, while they are rare in squamous-cell carcinomas and sarcomatoid carcinomas, and they do not occur in neuroendocrine carcinomas. Therefore, following intense discussion and in consensus with oncologists and pulmonologists, the Pulmonary Pathology Working Group of the Austrian Society of Pathology recommends a-priori EGFR mutation analysis for all adenocarcinoma cases, and for all other NSCLC cases upon clinical request. This will markedly reduce the waiting time for those patients who will most likely gain the greatest benefit from EGFR TKI therapy.

Keywords

Non–small-cell lung cancerEGFR-activating mutationsAdenocarcinomaTargeted therapy

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • H. Popper
    • 1
  • F. Wrba
    • 2
  • U. Gruber-Mösenbacher
    • 3
  • W. Hulla
    • 4
  • R. Pirker
    • 5
  • W. Hilbe
    • 6
  • M. Studnicka
    • 7
  • A. Mohn-Staudner
    • 8
  • F. Ploner
    • 9
  • Pulmonary Pathology Working Group of the Austrian Society of Pathology/International Academy of Pathology
  1. 1.Institute of PathologyMedical University of GrazGrazAustria
  2. 2.Institute of Clinical PathologyMedical University of ViennaViennaAustria
  3. 3.Institute of PathologyFeldkirch University Teaching HospitalFeldkirchAustria
  4. 4.Institute of PathologySMZ Süd – Kaiser Franz Josef Hospital and Gottfried von Preyer Childrens HospitalViennaAustria
  5. 5.Department of Internal Medicine I, OncologyMedical University of ViennaViennaAustria
  6. 6.Department of Internal Medicine V (Haematology and Oncology)Medical University of InnsbruckInnsbruckAustria
  7. 7.Department of PulmonologyParacelsus Private Medical University of SalzburgSalzburgAustria
  8. 8.Department of Pulmonology IISMZ Baumgartner Höhe/WienerwaldViennaAustria
  9. 9.Department of Internal Medicine, OncologyMedical University of GrazGrazAustria